Ascend Wellness Q2 Earnings Call Highlights

Ascend Wellness Holdings (OTCMKTS:AAWH) reported Q2 results on an earnings call. The Lansing, Michigan site stayed closed for repairs; the Illinois strike ended and operations resumed. Adjusted gross profit rose 8% sequentially to $58.3M, with adjusted gross margin at 46.2%. Cash was $67M. The company targets 60 stores by year-end and expects Q3 revenue growth of 2% to 4%.

Original reporting
Published Aug 13, 2026, 4:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 4:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ascend Wellness Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$AAWHNeutralMed
01

Why it matters

For traders, the key decision points are the Q3 sequential revenue growth range (2% to 4%), the expectation that adjusted EBITDA margin stays similar despite Illinois strike effects on wholesale, and the Aug. 28 shareholder vote on a proposed reverse stock split tied to a potential uplisting.

02

Market read

Q2 call highlights provide actionable near-term catalysts: explicit Q3 guidance, cash and capex trajectory, and a dated reverse-split vote, all within a regulatory and state-license constraint backdrop.

03

What to watch

Store ramp-ups, partner-store execution risk, and the timing and certainty of the federal hemp-loophole action could dominate outcomes more than product-launch volume.

Relevance 7/10Novelty 5/10Timing: pre-market today, with Aug. 28 reverse-split vote and Q3 guidance in focus

Background

Ascend Wellness Holdings discussed Q2 performance and outlook during its earnings call, including store growth, loyalty metrics, cash position, and regulatory catalysts.

Company-level read

Ticker impact

$AAWHNeutralMedium confidence
Context

Ascend reported Q2 call details including $67M cash, Q3 revenue growth guidance of 2% to 4%, and a planned reverse split vote Aug. 28.

Expected impact

Moderate volatility risk around the Aug. 28 shareholder vote and any follow-through on uplisting expectations; otherwise, price likely tracks Q3 margin and store ramp execution.

Evidence & confidence

The article provides concrete operational metrics (transactions, loyalty, store count), cash and capex, and explicit Q3 guidance, plus a specific corporate action date (reverse split vote). However, it is a call highlights recap rather than a fresh filing, limiting certainty on incremental new information versus already-known results.

Market effects

Highlights ongoing cannabis retail expansion constraints (license caps, moratoriums) and potential demand shift if a federal hemp loophole action takes effect before year-end.

Emphasizes state-by-state regulatory differences affecting growth cadence, especially Maryland’s ownership cap and moratorium versus New Jersey’s license cap increase.

Limited, as the story is primarily US state-regulated cannabis operations and a US federal regulatory catalyst.

Counterpoint

The M&A pipeline and reverse-split uplisting narrative may not translate into near-term earnings power, and Illinois wholesale disruption could pressure margins more than management expects.

Key entities

  • Ascend Wellness Holdings, Inc.

    OTC-listed cannabis consumer packaged goods and retail operator providing Q2 highlights, Q3 guidance, and an Aug. 28 reverse-split vote timeline.

  • Illinois union strike

    Disruption referenced as affecting July wholesale sales, partially offsetting Q3 revenue growth expectations.

  • Aug. 28 special meeting

    Shareholder vote scheduled for a proposed reverse stock split intended to support an uplisting requirement.

  • Federal action on the unregulated intoxicating-hemp loophole

    Management expects a federal action before year-end that could shift demand toward regulated cannabis channels.

Related articles

$AAWHMed

Ascend Wellness Holdings, Inc. (AAWH): AWH Reports Third Quarter 2026 Financial Results

Ascend Wellness Holdings, Inc. (AAWH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AWH Reports Third Quarter 2026 Financial Results Net revenue grew 4.2% year-over-year and 3.1% sequentially to $130.0 million in Q3 2026 Generated Adjusted EBITDA 1 of $31.1 million and Adjusted EBITDA Margin 1 of 23.9%, as revenue growth drove operating leverage End

$AAWHMed

Ascend Wellness Holdings, Inc. (AAWH): AWH Reports Second Quarter 2026 Financial Results

Ascend Wellness Holdings, Inc. (AAWH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AWH Reports Second Quarter 2026 Financial Results Generated Q2 2026 net revenue of $126.1 million and Adjusted EBITDA 1 of $29.1 million Scaled retail footprint to 55 locations, up from 48 at the end of Q1 2026 2 Grew market share by ~5% across our seven markets, ret

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.